PARSIPPANY, N.J. — Teva Pharmaceutical announced availability of the FDA-approved generic version of EpiPen Jr (epinephrine injection, USP) Auto-Injector, 0.15 mg, in the U.S. The product is available in most retail pharmacies, and the wholesale acquisition cost is $300 for a 2-pack.

“We’re pleased to provide access to Epinephrine Injection (Auto-Injector) in two strengths for patients who may experience life-threatening allergic emergencies,” said Brendan O’Grady, executive vice president and head of North America commercial. “We will continue working to ensure availability of both strengths in the US and plan to accelerate production to meet the urgent need for this medicine.”

With nearly 500 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the US. Currently, one in nine generic prescriptions dispensed in the US is filled with a Teva product.

Teva’s generic equivalent of EpiPen and EpiPen Jr utilize the Antares Pharma VIBEX device. Antares and Teva have an exclusive license, development and supply agreement for epinephrine auto injector products that Teva markets in the U.S.